Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease

Inclusion Criteria: * Subjects are between 50-85 years old, and clinical diagnosis of T2DM (HbA1c ≥ 6.5% or fasting plasma glucose ≥ 126 mg/dL or oral glucose tolerance test 2-hour plasma glucose ≥ 200 mg/dL). * Patients with stable pulmonary obstruction (pulmonary function FEV1/FVC \<0.7) with symptoms of pulmonary obstruction. * Subjects can cooperate with the collection of experimental specimens and return for regular visits. * The patient or family members have signed the informed consent form. * The patient must receive adjuvant treatment with probiotic for 12 weeks. Exclusion Criteria: * The patient or caregiver is unable to follow the physician's instructions for the trial, including the completed symptom assessment form and compliance with medication. * The patient has a history of related allergic reactions, or the use of other highly sensitive or contraindicated drugs (Allergy to antibiotics or antipyretics). * The patient have taken oral immunosuppressive drugs, intravenous steroids or T cell inhibitor ointments within the past 2 weeks. * The patient has consumed probiotic-related products (including drops, lozenges, capsules, powder and yogurt) within the past 1 month. * The patient received high doses of steroids within the past 1 month. * The patient with active infection or severe pulmonary disease (eg, tuberculosis, bronchiectasis, or fibrosis). * The patient is receiving treatment for a major disease or congenital disease. * The patient is not suitable to participate in the trial as assessed by the professional physician.